Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has executed a Memorandum of Understanding with the International Co-Innovation Centre for Advanced Medical Technology and Shenzhen Intelliphecy Life Technologies Co., Ltd. to develop and market the Company’s proprietary early lung cancer diagnostic tests based on the CIZ1B cancer biomarker in China.
Lung cancer is a major public health problem worldwide and especially in China, where it is still the most common diagnosed cancer and the leading cause of cancer related deaths. Early detection is essential in enabling early therapeutic intervention and improved outcomes.
iCCMAT, founded with German Medical Valley, Robert Bosch GmbH and Sinopharm Group, aims to accelerate global med-tech innovation in the Chinese market, by bringing together world leading expertise. The strategic alliance is intended to accelerate product development and clinical trials to achieve early adoption within major cancer centers throughout China.
The MOU is non-binding, but it is intended that a full commercial contract will be entered into in due course whereby the parties will collaborate closely in end-to-end development, manufacture and sale of early cancer detection products and services. The MOU envisages that iCCAMT and Intelliphecy will fund the activities in China and Cizzle Biotechnology will receive payment for monoclonal antibodies and reagents produced, and services provided, together with royalties on any sales of products and services in China.
Initial pilots of Cizzle Biotechnology’s lung cancer diagnostic tests are planned at the Cancer Hospital Chinese Academy of Medical Sciences, National Cancer Centre and Beijing Cancer Hospital affiliated with Peking University.
Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:
“We are delighted to establish this important collaboration to bring our simple blood test for the early detection of lung cancer based on the C1Z1B biomarker to China. In 2020, nearly 715,000 deaths were caused by lung cancer in China, accounting for around 24 percent of all the three million cancer deaths* there. It is a major health and economic challenge and together with our new partners we aim to contribute to building effective strategies for decreasing the cancer burden in China as part of their comprehensive prevention and control measures.”
Commenting, Dr Hui Wu, CEO and Founder of iCCAMT said:
“The C1Z1B biomarker developed by Cizzle Biotechnology has shown promising results for lung cancer early detection in the UK. To help the Chinese population access cost-efficient lung cancer detection, the iCCAMT would foster this technology implementation in China with support from its nationwide network of national clinical centers and key opinion leaders.”
Commenting, Dr Xiaoyun Huang, CEO and Founder of Intelliphecy said:
“The ability to detect lung cancer at an early stage is key for the improvement of patient survival and can eventually reduce the medical burden of lung cancer. We are excited to enter into partnership with Cizzle Biotechnology and iCCAMT to develop an early lung cancer diagnostic test based on Cizzle’s proprietary technology with the CIZ1B cancer biomarker. We are looking forward to reaching important milestones together with our partners in the near future.”
*https://www.statista.com/statistics/1053667/china-cancer-death-number-by-type/
